What is resistance? Impact of phenotypic versus molecular drug resistance testing on therapy for multi-and extensively drug-resistant tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 2, 2018, Pages

  Heyckendorf, Jan ^a,b,c   Andres, Sönke ^a   Köser, Claudio U ^d   Olaru, Ioana D ^a,b   Schön, Thomas ^e,f   Sturegård, Erik ^g   Beckert, Patrick ^a,b   Schleusener, Viola ^a   Kohl, Thomas A ^a,b   Hillemann, Doris ^a   Moradigaravand, Danesh ^h   Parkhill, Julian ^h   Peacock, Sharon J ^d,h,i   Niemann, Stefan ^a,b   Lange, Christoph ^a,b,c,j,k   Merkerb, Matthias ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

^b Research Center Borstel   (Germany)

^c UNIVERSITY OF LÜBECK   (Germany)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e KALMAR COUNTY HOSPITAL   (Sweden)

^f LINKÖPING UNIVERSITY   (Sweden)

^g LUND UNIVERSITY   (Sweden)

^h WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

ⁱ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^j KAROLINSKA INSTITUTE   (Sweden)

^k UNIVERSITY OF NAMIBIA   (Namibia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; BEDAQUILINE; CAPREOMYCIN; CLOFAZIMINE; CYCLOSERINE; DELAMANID; ETHAMBUTOL; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; TERIZIDONE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE MUTATION; GENOTYPE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; WHOLE GENOME SEQUENCING; BACTERIAL GENOME; BACTERIUM IDENTIFICATION; DRUG EFFECT; GENETICS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ANTITUBERCULAR AGENTS; BACTERIAL TYPING TECHNIQUES; COHORT STUDIES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENOME, BACTERIAL; GENOTYPE; HUMANS; KANAMYCIN; LEVOFLOXACIN; MICROBIAL SENSITIVITY TESTS; MOXIFLOXACIN; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT; WHOLE GENOME SEQUENCING;

EID: 85040981340     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01550-17     Document Type: Article

References (61)

1. World Health Organization. 2016. Global tuberculosis report. World Health Organization, Geneva, Switzerland. http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf?ua1.
2. Lange C, Abubakar I, Alffenaar JWC, Bothamley G, Caminero Ja Carvalho ACC, Chang KC, Codecasa L, Correia A, Crudu V, Davies P, Dedicoat M, Drobniewski F, Duarte R, Ehlers C, Erkens C, Goletti D, Günther G, Ibraim E, Kampmann B, Kuksa L, De Lange W, Van Leth F, Van Lunzen J, Matteelli A, Menzies D, Monedero I, Richter E, Rüsch-Gerdes S, Sandgren A, Scardigli A, Skrahina A, Tortoli E, Volchenkov G, Wagner D, Van Der Werf MJ, Williams B, Yew WW, Zellweger JP, Cirillo DM. 2014. Management of patients with multidrugresistant/ extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 44:23–63. https://doi.org/10.1183/09031936.00188313.
3. Horsburgh CR, Jr, Barry CE, III, Lange C. 2015. Treatment of tuberculosis. N Engl J Med 373:2149–2160. https://doi.org/10.1056/NEJMra1413919.
4. Köser CU, Ellington MJ, Cartwright EJ, Gillespie SH, Brown NM, Far-rington M, Holden MT, Dougan G, Bentley SD, Parkhill J, Peacock SJ. 2012. Routine use of microbial whole genome sequencing in diagnostic and public health microbiology. PLoS Pathog 8:e1002824. https://doi.org/10.1371/journal.ppat.1002824.
5. Köser CU, Bryant JM, Becq J, Török ME, Ellington MJ, Marti-Renom MA, Carmichael AJ, Parkhill J, Smith GP, Peacock SJ. 2013. Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis. N Engl J Med 369:290–292. https://doi.org/10.1056/NEJMc1215305.
6. Schön T, Miotto P, Köser CU, Viveiros M, Böttger E, Cambau E. 2017. Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives. Clin Microbiol Infect 23:154–160. https://doi.org/10.1016/j.cmi.2016.10.022.
7. Boehme CC, Nabeta P, Hillemann D. 2010. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363:1005–1015. https://doi.org/10.1056/NEJMoa0907847.
8. Walker TM, Kohl TA, Omar SV, Hedge J, Del Ojo Elias C, Bradley P, Iqbal Z, Feuerriegel S, Niehaus KE, Wilson DJ, Clifton DA, Kapatai G, Ip CL, Bowden R, Drobniewski FA, Allix-Beguec C, Gaudin C, Parkhill J, Diel R, Supply P, Crook DW, Smith EG, Walker AS, Ismail N, Niemann S, Peto TE, Modernizing Medical Microbiology Informatics Group. 2015. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis 15:1193–1202. https://doi.org/10.1016/S1473-3099(15)00062-6.
9. McNerney R, Clark TG, Campino S, Rodrigues C, Dolinger D, Smith L, Cabibbe AM, Dheda K, Schito M. 2017. Removing the bottleneck in whole genome sequencing of Mycobacterium tuberculosis for rapid drug resistance analysis: a call to action. Int J Infect Dis 56:130 –135. https://doi.org/10.1016/j.ijid.2016.11.422.
10. Walker TM, Merker M, Kohl TA, Crook DW, Niemann S, Peto TEA. 2016. Whole genome sequencing for M/XDR tuberculosis surveillance and for resistance testing. Clin Microbiol Infect 23:161–166. https://doi.org/10.1016/j.cmi.2016.10.014.
11. Clinical and Laboratory Standards Institute. 2011. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes, 2nd ed. Approved standard. CLSI document M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Ängeby K, Juréen P, Kahlmeter G, Hoffner SE, Schön T. 2012. Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull World Health Organ 90:693– 698. https://doi.org/10.2471/BLT.11.096644.
13. Schön T, Juréen P, Chryssanthou E, Giske CG, Kahlmeter G, Hoffner S, Ängeby K. 2013. Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact? J Antimicrob Chemother 68:2074–2077. https://doi.org/10.1093/jac/dkt150.
14. World Health Organization. 2014. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization, Geneva, Switzerland. http:// appswhoint/iris/bitstream/10665/130918/1/9789241548809_engpdf ?ua1&ua1.
15. Ellington MJ, Ekelund O, Aarestrup FM, Canton R, Doumith M, Giske C, Grundman H, Hasman H, Holden MT, Hopkins KL, Iredell J, Kahlmeter G, Koser CU, MacGowan A, Mevius D, Mulvey M, Naas T, Peto T, Rolain JM, Samuelsen O, Woodford N. 2017. The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee. Clin Microbiol Infect 23:2–22. https://doi.org/10.1016/j.cmi.2016.11.012.
16. Kahlmeter G. 2015. The 2014 Garrod lecture: EUCAST–are we heading towards international agreement? J Antimicrob Chemother 70: 2427–2439. https://doi.org/10.1093/jac/dkv145.
17. Berrada ZL, Lin SY, Rodwell TC, Nguyen D, Schecter GF, Pham L, Janda JM, Elmaraachli W, Catanzaro A, Desmond E. 2016. Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex. Diagn Microbiol Infect Dis 85: 177–181. https://doi.org/10.1016/j.diagmicrobio.2016.01.019.
18. Domínguez J, Boettger EC, Cirillo D, Cobelens F, Eisenach KD, Gagneux S, Hillemann D, Horsburgh R, Molina-Moya B, Niemann S, Tortoli E, Whitelaw A, Lange C, TBNET, RESIST-TB Networks. 2016. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement. Int J Tuberc Lung Dis 20:24–42. https://doi.org/10.5588/ijtld.15.0221.
19. Machado D, Perdigão J, Ramos J, Couto I, Portugal I, Ritter C, Boettger EC, Viveiros M. 2013. High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations. J Antimicrob Chemother 68: 1728 –1732. https://doi.org/10.1093/jac/dkt090.
20. Nathavitharana RR, Hillemann D, Schumacher SG, Schlueter B, Ismail N, Omar SV, Sikhondze W, Havumaki J, Valli E, Boehme C, Denkinger CM. 2016. Multicenter noninferiority evaluation of Hain GenoType MTBDRplus version 2 and Nipro NTMMDRTB line probe assays for detection of rifampin and isoniazid resistance. J Clin Microbiol 54: 1624–1630. https://doi.org/10.1128/JCM.00251-16.
21. Ando H, Miyoshi-Akiyama T, Watanabe S, Kirikae T. 2014. A silent mutation in mabA confers isoniazid resistance on Mycobacterium tuberculosis. Mol Microbiol 91:538–547. https://doi.org/10.1111/mmi.12476.
22. Dover LG, Alahari A, Gratraud P, Gomes JM, Bhowruth V, Reynolds RC, Besra GS, Kremer L. 2007. EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets. Antimicrob Agents Chemother 51:1055–1063. https://doi.org/10.1128/AAC.01063-06.
23. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, Cambau E, Aubry A. 2012. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 67:819–831. https://doi.org/10.1093/jac/dkr566.
24. Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Husain A, Hussain A, Ismail N, Kamal M, Mansjo M, Mvusi L, Niemann S, Omar SV, Qadeer E, Rigouts L, Ruesch-Gerdes S, Schito M, Seyfaddinova M, Skrahina A, Tahseen S, Wells WA, Mukadi YD, Kimerling M, Floyd K, Weyer K, Raviglione MC. 2016. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis 16: 1185–1192. https://doi.org/10.1016/S1473-3099(16)30190-6.
25. Zaunbrecher MA, Sikes RD, Jr, Metchock B, Shinnick TM, Posey JE. 2009. Overexpression of the chromosomally encoded aminoglycoside acetyl-transferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 106:20004 –20009. https://doi.org/10.1073/pnas.0907925106.
26. Reeves AZ, Campbell PJ, Sultana R, Malik S, Murray M, Plikaytis BB, Shinnick TM, Posey JE. 2013. Aminoglycoside cross-resistance in Mycobacterium tuberculosis due to mutations in the 5= untranslated region of whiB7. Antimicrob Agents Chemother 57:1857–1865. https://doi.org/10.1128/AAC.02191-12.
27. Kambli P, Ajbani K, Nikam C, Sadani M, Shetty A, Udwadia Z, Georghiou SB, Rodwell TC, Catanzaro A, Rodrigues C. 2016. Corrigendum to “Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables” [Int J Mycobacteriol 5(1) 2016 1–6]. Int J Mycobacteriol 5:370–372. https://doi.org/10.1016/j.ijmyco.2016.06.009.
28. Maus CE, Plikaytis BB, Shinnick TM. 2005. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 49:571–577. https://doi.org/10.1128/AAC.49.2.571-577.2005.
29. Finken M, Kirschner P, Meier A, Wrede A, Böttger E. 1993. Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot. Mol Microbiol 9:1239 –1246. https://doi.org/10.1111/j.1365-2958.1993.tb01253.x.
30. Dymova MA, Cherednichenko AG, Alkhovik OI, Khrapov EA, Petrenko TI, Filipenko ML. 2014. Characterization of extensively drug-resistant Mycobacterium tuberculosis isolates circulating in Siberia. BMC Infect Dis 14:478. https://doi.org/10.1186/1471-2334-14-478.
31. Miotto P, Cabibbe AM, Feuerriegel S, Casali N, Drobniewski F, Rodionova Y, Bakonyte D, Stakenas P, Pimkina E, Augustynowicz-Kopec E, Degano M, Ambrosi A, Hoffner S, Mansjo M, Werngren J, Rüsch-Gerdes S, Niemann S, Cirillo DM. 2014. Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study. mBio 5:e01819-14. https://doi.org/10.1128/mBio.01819-14.
32. Tekwu EM, Sidze LK, Assam JP, Tedom JC, Tchatchouang S, Makafe GG, Wetewale AL, Kuaban C, Eyangoh S, Ntoumi F, Beng VN, Frank M. 2014. Sequence analysis for detection of drug resistance in Mycobacterium tuberculosis complex isolates from the Central Region of Cameroon. BMC Microbiol 14:113. https://doi.org/10.1186/1471-2180-14-113.
33. Ramirez-Busby SM, Valafar F. 2015. Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 59: 5267–5277. https://doi.org/10.1128/AAC.00204-15.
34. Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, Hooks DP, Cowan LS, Plikaytis BB, Posey JE. 2011. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 55:2032–2041. https://doi.org/10.1128/AAC.01550-10.
35. Cui Z, Li Y, Cheng S, Yang H, Lu J, Hu Z, Ge B. 2014. Mutations in the embC-embA intergenic region contribute to Mycobacterium tuberculosis resistance to ethambutol. Antimicrob Agents Chemother 58:6837–6843. https://doi.org/10.1128/AAC.03285-14.
36. Nebenzahl-Guimaraes H, Jacobson KR, Farhat MR, Murray MB. 2014. Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 69:331–342. https://doi.org/10.1093/jac/dkt358.
37. Desjardins CA, Cohen KA, Munsamy V, Abeel T, Maharaj K, Walker BJ, Shea TP, Almeida DV, Manson AL, Salazar A, Padayatchi N, O’Donnell MR, Mlisana KP, Wortman J, Birren BW, Grosset J, Earl AM, Pym AS. 2016. Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance. Nat Genet 48:544 –551. https://doi.org/10.1038/ng.3548.
38. Günther G, Leth FV, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Danilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, Lange WD, Leimane V, Magis-Escurra C, McLaughlin A-M, Muylle I, Polcová V, Pontali E, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, Lange C. 2015. Multidrug-resistant tuberculosis in Europe, 2010–2011. Emerg Infect Dis 21: 2010–2011.
39. Günther G, van Leth F, Altet N, Dedicoat M, Duarte R, Gualano G, Kunst H, Muylle I, Spinu V, Tiberi S, Viiklepp P, Lange C, TBNET. 2015. Beyond multidrug-resistant tuberculosis in Europe: a TBNET study. Int J Tuberc Lung Dis 19:1524–1527.
40. Böttger EC. 2011. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin Microbiol Infect 17:1128–1134. https://doi.org/10.1111/j.1469-0691.2011.03551.x.
41. Safi H, Lingaraju S, Amin A, Kim S, Jones M, Holmes M, McNeil M, Peterson SN, Chatterjee D, Fleischmann R, Alland D. 2013. Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl--D-arabinose biosynthetic and utilization pathway genes. Nat Genet 45:1190–1197. https://doi.org/10.1038/ng.2743.
42. Yakrus MA, Driscoll J, McAlister A, Sikes D, Hartline D, Metchock B, Starks AM. 2016. Molecular and growth-based drug susceptibility testing of Mycobacterium tuberculosis complex for ethambutol resistance in the United States. Tuberc Res Treat 2016:3404860.
43. Sirgel FA, Warren RM, Böttger EC, Klopper M, Victor TC, van Helden PD. 2013. The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks. PLoS One 8:e59414. https://doi.org/10.1371/journal.pone.0059414.
44. Van Deun A, Aung KJ, Bola V, Lebeke R, Hossain MA, de Rijk WB, Rigouts L, Gumusboga A, Torrea G, de Jong BC. 2013. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 51:2633–2640. https://doi.org/10.1128/JCM.00553-13.
45. Gonzalo X, Claxton P, Brown T, Montgomery L, Fitzgibbon M, Laurenson I, Drobniewski F. 2017. True rifampicin resistance missed by the MGIT: prevalence of this pheno/genotype in the UK and Ireland after 18 month surveillance. Clin Microbiol Infect 23:260 –263. https://doi.org/10.1016/j.cmi.2016.11.015.
46. Casali N, Nikolayevskyy V, Balabanova Y, Harris SR, Ignatyeva O, Kontsevaya I, Corander J, Bryant J, Parkhill J, Nejentsev S, Horstmann RD, Brown T, Drobniewski F. 2014. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet 46:279–286. https://doi.org/10.1038/ng.2878.
47. Merker M, Blin C, Mona S, Duforet-Frebourg N, Lecher S, Willery E, Blum MG, Rüsch-Gerdes S, Mokrousov I, Aleksic E, Allix-Beguec C, Antierens A, Augustynowicz-Kopec E, Ballif M, Barletta F, Beck HP, Barry CE, III, Bonnet M, Borroni E, Campos-Herrero I, Cirillo D, Cox H, Crowe S, Crudu V, Diel R, Drobniewski F, Fauville-Dufaux M, Gagneux S, Ghebremichael S, Hanekom M, Hoffner S, Jiao WW, Kalon S, Kohl TA, Kontsevaya I, Lille-baek T, Maeda S, Nikolayevskyy V, Rasmussen M, Rastogi N, Samper S, Sanchez-Padilla E, Savic B, Shamputa IC, Shen A, Sng LH, Stakenas P, Toit K, Varaine F, Vukovic D, Wahl C, Warren R, Supply P, Niemann S, Wirth T. 2015. Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage. Nat Genet 47:242–249. https://doi.org/10.1038/ng.3195.
48. European Committee for Antimicrobial Susceptibility Testing. 2017. EUCAST subcommittee on MIC distributions and epidemiological cut-off values (ECOFFs). Discussion document, version 3. http://www.eucast.org/organization/subcommittees/mic_distributions_and _ecoffs/.
49. Hofmann-Thiel S, Hoffmann H, Hillemann D, Rigouts L, Van Deun A, Kranzer K. 2017. How should discordance between molecular and growth-based assays for rifampicin resistance be investigated? Int J Tuberc Lung Dis 21:721–726. https://doi.org/10.5588/ijtld.17.0140.
50. van Embden JD, Cave MD, Crawford JT, Dale JW, Eisenach KD, Gicquel B, Hermans P, Martin C, McAdam R, Shinnick TM, Small PM. 1993. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 31: 406–409.
51. Baym M, Kryazhimskiy S, Lieberman TD, Chung H, Desai MM, Kishony R. 2015. Inexpensive multiplexed library preparation for megabase-sized genomes. PLoS One 10:e0128036. https://doi.org/10.1371/journal.pone .0128036.
52. Tagliani E, Cabibbe AM, Miotto P, Borroni E, Toro JC, Mansjo M, Hoffner S, Hillemann D, Zalutskaya A, Skrahina A, Cirillo DM. 2015. Diagnostic performance of the new version of GenoType MTBDRsl (V2.0) assay for detection of resistance to fluoroquinolones and second line injectable drugs: a multicenter study. J Clin Microbiol 53:2961–2969. https://doi.org/10.1128/JCM.01257-15.
53. Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25:1754–1760. https://doi.org/10.1093/bioinformatics/btp324.
54. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. 2010. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20:1297–1303. https://doi.org/10.1101/gr.107524.110.
55. Köser CU, Feuerriegel S, Summers DK, Archer JA, Niemann S. 2012. Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance. Antimicrob Agents Chemother 56:6080–6087. https://doi.org/10.1128/AAC.01641-12.
56. Feuerriegel S, Köser CU, Niemann S. 2014. Phylogenetic polymorphisms in antibiotic resistance genes of the Mycobacterium tuberculosis complex. J Antimicrob Chemother 69:1205–1210. https://doi.org/10.1093/jac/dkt535.
57. Nosova EY, Bukatina AA, Isaeva YD, Makarova MV, Galkina KY, Moroz AM. 2013. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin. J Med Microbiol 62:108 –113. https://doi.org/10.1099/jmm.0.046821-0.
58. Kambli P, Ajbani K, Nikam C, Khillari A, Shetty A, Udwadia Z, Georghiou SB, Rodwell TC, Catanzaro A, Rodrigues C. 2015. Determination of MICs of levofloxacin for Mycobacterium tuberculosis with gyrA mutations. Int J Tuberc Lung Dis 19:1227–1229. https://doi.org/10.5588/ijtld.14.0277.
59. Malik S, Willby M, Sikes D, Tsodikov OV, Posey JE. 2012. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS One 7:e39754. https://doi.org/10.1371/journal.pone.0039754.
60. Reeves AZ, Campbell PJ, Willby MJ, Posey JE. 2015. Disparities in capreomycin resistance levels associated with the rrs A1401G mutation in clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 59:444–449. https://doi.org/10.1128/AAC.04438-14.
61. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. 2008. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 system. Int J Tuberc Lung Dis 12: 1449–1455.